Paper
Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure.
Published Aug 28, 2007 · B. López, Arantxa González, J. Beaumont
Journal of the American College of Cardiology
Q1 SJR score
130
Citations
4
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Non-RCT
Highly CitedStudy Snapshot
Torasemide reduces myocardial fibrosis in chronic heart failure patients by decreasing PCP activation.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
The relationship between myocardial extracellular matrix remodeling and ventricular function.
Altered collagen quantity and quality can negatively impact ventricular function, and focusing on collagen cross-linking may prevent adverse effects on myocardial remodeling.
2006·283citations·G. Brower et al.·European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure.
The pattern of collagen deposits and the balance of MMP-1/TIMP-1 system are different in the myocardium of systolic heart failure (SHF) and diastolic heart failure (DHF) hypertensive patients, suggesting excessive degradation of mysial collagen may contribute to s
2006·251citations·B. López et al.·Journal of the American College of Cardiology
Journal of the American College of Cardiology
Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease.
Post-transcriptional regulation of PPARalpha isoforms is altered in patients with hypertensive heart disease, with an excess of the truncated inhibitory isoform potentially contributing to hypertensive left ventricular failure and remodeling.
2006·52citations·M. J. Goikoetxea et al.·Cardiovascular research
Cardiovascular research
Expression of procollagen C-proteinase enhancer-1 in the remodeling rat heart is stimulated by aldosterone.
Aldosterone stimulates PCPE-1 expression in the remodeling myocardium after infarction, suggesting it as a potential target for intervention with cardiac fibrosis.
2006·37citations·G. Kessler‐Icekson et al.·The international journal of biochemistry & cell biology
The international journal of biochemistry & cell biology
Diverse biological functions of extracellular collagen processing enzymes
Extracellular collagen processing enzymes have diverse biological functions, including maintaining normal cellular phenotypes and tissue integrity.
2005·130citations·P. Trackman·Journal of Cellular Biochemistry
Journal of Cellular Biochemistry
Different effects of long- and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats.
Azosemide provides better prognosis in heart failure rats compared to furosemide, partly due to attenuation of cardiac sympathetic neuronal activity.
2005·28citations·Junichi Yoshida et al.·Cardiovascular research
Cardiovascular research
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article
The 2005 ACC/AHA guideline update for chronic heart failure diagnosis and management emphasizes the importance of early detection and effective treatment.
2005·2237citations·S. A. Hunt et al.·Circulation
Circulation
New directions in the assessment and treatment of hypertensive heart disease
New approaches to assess and repair myocardial fibrosis may help reduce adverse risks associated with hypertensive heart disease.
2005·14citations·Arantxa González et al.·Current Opinion in Nephrology and Hypertension
Current Opinion in Nephrology and Hypertension
Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin: Relation to Myocardial Fibrosis
Increased collagen type I synthesis and deposition may contribute to the development of heart failure in hypertensive heart disease patients, making peripheral blood PIP measurements a useful marker for myocardial fibrosis.
2004·407citations·R. Querejeta et al.·Circulation
Circulation
Citations
Torsemide vs. furosemide in congestive heart failure: a systematic-review and meta-analysis on mortality and rehospitalization.
Torsemide compared to furosemide in heart failure patients did not result in statistically significant differences in all-cause mortality or rehospitalization rates.
2025·0citations·Nino Gudushauri et al.·Acta cardiologica
Acta cardiologica
Chinese and western medicine treatment of myocardial fibrosis drugs
Traditional Chinese medicine, with multiple targets and low cost, can improve myocardial fibrosis treatment, offering potential for clinical treatment and research.
2025·0citations·Yuxi Zhu et al.·Frontiers in Cardiovascular Medicine
Frontiers in Cardiovascular Medicine
TRANSFORM-HF Trial: Choice of loop diuretic in acute heart failure does not matter!
In acute heart failure, there is no benefit of choosing between torsemide and furosemide, and the focus should be on optimizing diuretic dose and other guideline-based therapies rather than choosing between the two.
2024·0citations·A. Pradhan et al.·Journal of Family Medicine and Primary Care
Journal of Family Medicine and Primary Care
Hitting the Target! Challenges and Opportunities for TGF-β Inhibition for the Treatment of Cardiac fibrosis
TGF- inhibition shows promise in reducing cardiac fibrosis, but overcoming adverse effects and identifying appropriate targets is crucial for its clinical implementation.
2024·3citations·Maria Vistnes·Pharmaceuticals
Pharmaceuticals
Rationale and protocol of the LAQUA-HF trial: a factorial randomised controlled trial evaluating the effects of neurohormonal and diuretic agents on health-status reported outcomes in heart failure patients
The LAQUA-HF trial aims to determine the optimal sequence of cardioprotective drugs and diuretics for heart failure patients, with a focus on improving health-status and quality-of-life.
2024·1citation·Y. Shiraishi et al.·BMJ Open
BMJ Open
Myocardial Interstitial Fibrosis in Hypertensive Heart Disease: From Mechanisms to Clinical Management
Myocardial interstitial fibrosis contributes to maladaptive structural remodeling and poor outcomes in hypertensive heart disease patients, and more research is needed to effectively diagnose and treat this condition.
2023·8citations·Arantxa González et al.·Hypertension
Hypertension
Drugs for treating myocardial fibrosis
Modern medicines and traditional Chinese medicines can effectively treat myocardial fibrosis by affecting signaling pathways and inhibiting protein synthesis.
2023·5citations·Zhanhong Ren et al.·Frontiers in Pharmacology
Frontiers in Pharmacology
Non-Ischemic Myocardial Fibrosis in End-Stage Kidney Disease Patients: A New Perspective
Non-ischemic myocardial fibrosis in end-stage kidney disease patients is associated with a poorer prognosis, and its treatment is crucial for improving outcomes.
2023·0citations·Kenji Nakata et al.·Kidney and Dialysis
Kidney and Dialysis